Versigent (NYSE:VGNT) Posts Quarterly Earnings Results, Beats Expectations By $0.12 EPS

Versigent (NYSE:VGNT) issued its earnings results on Wednesday. The company reported $1.91 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.12, Zacks reports. The firm had revenue of $2.45 billion during the quarter, compared to the consensus estimate of $2.42 billion.

Here are the key takeaways from Versigent’s conference call:

• Versigent reported 7% sales growth, 11% higher adjusted EBITDA, and 40 basis points of margin expansion; adjusted sales grew about 1% despite global automotive production declining approximately 2%. This marked its sixth consecutive quarter of growth over market.
• The company raised its 2026 free-cash-flow guidance to $275 million–$325 million, citing stronger year-to-date performance and the timing of some initiatives. The higher sales outlook reflects increased copper pass-throughs, while the adjusted EBITDA midpoint remains unchanged at $990 million.
• Versigent reported more than 115 program launches so far this year, with over 99% quality and on-time delivery, and secured $7.5 billion in year-to-date bookings. Management said the launches and awards demonstrate its ability to execute complex programs and support future growth.
• EMEA adjusted sales fell 8% amid weak demand, lower vehicle production, and program roll-offs. Elevated fourth-quarter launch activity and the lag in copper-cost recovery may also pressure sequential margins; management cautioned that third-quarter margins are not a new run rate.
• Adjacent markets such as battery energy storage, power generation, and robotics are generating early wins, but many programs remain in development or small-scale production. Management said these opportunities are not expected to contribute meaningfully to its current outlook.

Versigent Price Performance

NYSE VGNT traded up $1.23 on Friday, hitting $41.51. The stock had a trading volume of 377,987 shares, compared to its average volume of 1,518,457. Versigent has a 52-week low of $26.34 and a 52-week high of $50.88. The company has a debt-to-equity ratio of 5.69, a quick ratio of 1.09 and a current ratio of 1.43. The company has a market capitalization of $2.94 billion and a price-to-earnings ratio of 21.62. The firm has a 50-day moving average of $44.93 and a 200-day moving average of $42.69.

Versigent Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 17th. Stockholders of record on Friday, December 4th will be issued a $0.13 dividend. This represents a $0.52 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend is Friday, December 4th.

Insider Buying and Selling

In related news, Director Kevin Clark sold 74,130 shares of the firm’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $45.67, for a total value of $3,385,517.10. Following the sale, the director directly owned 124,849 shares of the company’s stock, valued at $5,701,853.83. This trade represents a 37.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold 220,000 shares of company stock worth $10,065,848 in the last three months.

Analyst Ratings Changes

Several equities research analysts recently issued reports on VGNT shares. Weiss Ratings upgraded Versigent from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Oppenheimer set a $50.00 price objective on Versigent in a research note on Tuesday, July 21st. Evercore reaffirmed an “outperform” rating and set a $65.00 price objective on shares of Versigent in a report on Monday, August 10th. Argus upped their target price on shares of Versigent from $50.00 to $54.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Finally, Fox Advisors downgraded shares of Versigent from an “overweight” rating to an “equal weight” rating in a report on Wednesday, August 5th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $55.08.

Key Stories Impacting Versigent

Here are the key news stories impacting Versigent this week:

• Positive Sentiment: TD Cowen raised its target to $59 from $58 and maintained a Buy rating, implying substantial potential upside from the recent share price. Article: Versigent Stock Price Target Raised at TD Cowen
• Positive Sentiment: Versigent reported third-quarter EPS of $1.91, above the $1.79 consensus estimate, and revenue of $2.45 billion versus expectations of $2.42 billion. Its earnings call also highlighted growth despite market pressures. Article: Versigent Earnings Call Shows Growth Despite Market Pressures
• Positive Sentiment: The company declared a quarterly dividend of $0.13 per share, equivalent to $0.52 annually and a yield of about 1.2%.
• Neutral Sentiment: CFO Doug Ostermann is scheduled to participate in an RBC Capital Markets industrials conference on November 17; the announcement did not include new financial guidance. Article: Versigent CFO to Participate in RBC Capital Markets Global Industrials Conference
• Negative Sentiment: Royal Bank of Canada lowered its target to $52 from $53, though it kept an Outperform rating. Article: Versigent Stock Price Target Lowered at Royal Bank of Canada
• Negative Sentiment: BNP Paribas Exane reaffirmed Outperform but reduced its target to $54 from $55, signaling a modestly less optimistic valuation view. Article: Versigent’s Outperform Rating Reaffirmed at BNP Paribas Exane

About Versigent

Versigent PLC is involved in the design, manufacturing and delivery of low and high voltage power electrical architectures. Versigent PLC is based in SCHAFFHAUSEN, Switzerland.